Reneo Pharmaceuticals, Inc.
NASDAQ:RPHM
Overview | Financials
Company Name | Reneo Pharmaceuticals, Inc. |
Symbol | RPHM |
Currency | USD |
Price | 18.2 |
Market Cap | 60,840,416 |
Dividend Yield | 0% |
52-week-range | 1.68 - 82.9 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Gregory J. Flesher |
Website | https://reneopharma.com |
An error occurred while fetching data.
About Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD